| Issue Date |
Title |
Author(s) |
| Jun-2021 |
Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study |
Dou, Xuelin;Zheng, Fangyuan;Zhang, Liqiang;Jin, Jie;Zhang, Yanli;Liu, Bingcheng;Meng, Li;Zhu, Xiaofan;Lu, Zesheng;Jia, Yueping;Liu, Huilan;Lin, Hai;Zhou, Li;Zhao, Xielan;Yang, Wei;Sun, Hui;Qian, Sixuan;Ma, Hongxia;Du, Xin;Bai, Qingxian;Xu, Na;Meng, Fanjun;Jia, Zhilin;Di, Haixia;Zhang, Leping;Jiang, Qian |
| 15-Nov-2022 |
A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China |
Jiang, Qian;Li, Zongru;Qin, Ya-Zhen;Zhao, Ting;Liu, Bingcheng;Chen, Zi;Niu, Qian;Men, Lichuang;Wang, Hengbang;Yang, Dajun;Zhai, Yifan;Huang, Xiao-Jun |
| 1-Jan-2021 |
Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study |
Zhang, Li;Meng, Li;Liu, Bingcheng;Zhang, Yanli;Zhu, Huanling;Cui, Jiuwei;Sun, Aining;Hu, Yu;Jin, Jie;Jiang, Hao;Zhang, Xi;Li, Yan;Liu, Li;Zhang, Wanggang;Liu, Xiaoli;Gu, Jian;Qiao, Jianhui;Ouyang, Guifang;Liu, Xin;Luo, Jianmin;Jiang, Ming;Xie, Xiaobao;Li, Jianyong;Zhao, Chunting;Zhang, Mei;Yang, Tonghua;Wang, Jianxiang |
| 2019 |
Frontline flumatinib versus imatinib in patients with chronic myeloid leukemia in chronic phase: Results from the China randomized phase III study. |
Li, Zhang;Meng, Li;Zhang, Yanli;Zhu, Huanling;Cui, Jiuwei;Sun, Aining;Hu, Yu;Jin, Jie;Jiang, Hao;Zhang, Xi;Li, Yan;Liu, Qifa;Liu, Li;Zhang, Wanggang;Gu, Jian;Qiao, Jian-Hui;Liu, Bingcheng;Zhang, Fengkui;Guo, Yong;Wang, Jianxiang |
| 15-Nov-2022 |
Is the 2nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study |
Yang, Sen;Zhang, Xiaoshuai;Zhang, Yanli;Du, Xin;Weng, Jianyu;Zhu, Huanling;Pan, Ling;Yang, Yun-fan;Meng, Li;Liu, Zhenfang;Liu, Xiaoli;Xu, Na;Chen, Chunyan;Wang, Xiaodong;Liang, Rong;Huang, Jian;Li, Guohui;Liu, Chunshui;Lin, Hai;Hu, Jianda;Fei, Li;Liu, Bingcheng;Li, Weiming;Liu, Zhuogang;Yang, Wei;Huang, Xiao Jun;Jiang, Qian |
| 8-Jun-2021 |
Mental Health in Persons With Chronic Myeloid Leukemia During the SARS-CoV-2 Pandemic: The Need for Increased Access to Health Care Services |
Bao, Mei;Yang, Sen;Gale, Robert Peter;Zhang, Yanli;Liu, Xiaoli;Zhu, Huanling;Liang, Rong;Liu, Bingcheng;Zhou, Li;Li, Zongru;Dou, Xuelin;Shi, Dayu;Wang, Tao;Meng, Li;Li, Weiming;Jiang, Qian |
| 18-Aug-2022 |
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial |
Jiang, Qian;Li, Zongru;Qin, Yazhen;Li, Weiming;Xu, Na;Liu, Bingcheng;Zhang, Yanli;Meng, Li;Zhu, Huanling;Du, Xin;Chen, Suning;Liang, Yang;Hu, Yu;Liu, Xiaoli;Song, Yongping;Men, Lichuang;Chen, Zi;Niu, Qian;Wang, Hengbang;Lu, Ming;Yang, Dajun;Zhai, Yifan;Huang, Xiaojun |
| 31-Oct-2022 |
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 113, 2022) |
Jiang, Qian;Li, Zongru;Qin, Yazhen;Li, Weiming;Xu, Na;Liu, Bingcheng;Zhang, Yanli;Meng, Li;Zhu, Huanling;Du, Xin;Chen, Suning;Liang, Yang;Hu, Yu;Liu, Xiaoli;Song, Yongping;Men, Lichuang;Chen, Zi;Niu, Qian;Wang, Hengbang;Lu, Ming;Yang, Dajun;Zhai, Yifan;Huang, Xiaojun |
| 20-Feb-2023 |
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 159, 2022) |
Jiang, Qian;Li, Zongru;Qin, Yazhen;Li, Weiming;Xu, Na;Liu, Bingcheng;Zhang, Yanli;Meng, Li;Zhu, Huanling;Du, Xin;Chen, Suning;Liang, Yang;Hu, Yu;Liu, Xiaoli;Song, Yongping;Men, Lichuang;Chen, Zi;Niu, Qian;Wang, Hengbang;Lu, Ming;Yang, Dajun;Zhai, Yifan;Huang, Xiaojun |
| 15-Nov-2022 |
A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy |
Zhang, Xiaoshuai;Liu, Bingcheng;Huang, Jian;Zhang, Gongli;Liu, Xiaoli;Xu, Na;Li, Weiming;Du, Xin;Weng, Jianyu;Lin, Hai;Liang, Rong;Chen, Chunyan;Zhu, Huanling;Pan, Ling;Yang, Yun-fan;Wang, Xiaodong;Li, Guohui;Liu, Zhuogang;Liu, Zhenfang;Hu, Jianda;Liu, Chunshui;Fei, Li;Yang, Wei;Meng, Li;Gale, Robert Peter;Huang, Xiao Jun;Jiang, Qian |
| 15-Nov-2022 |
Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor |
Zhang, Xiaoshuai;Liu, Bingcheng;Huang, Jian;Zhang, Gongli;Liu, Xiaoli;Xu, Na;Li, Weiming;Du, Xin;Weng, Jianyu;Lin, Hai;Liang, Rong;Chen, Chunyan;Zhu, Huanling;Pan, Ling;Yang, Yun-fan;Wang, Xiaodong;Li, Guohui;Liu, Zhuogang;Liu, Zhenfang;Hu, Jianda;Liu, Chunshui;Fei, Li;Yang, Wei;Meng, Li;Gale, Robert Peter;Huang, Xiao Jun;Jiang, Qian |
| 23-Nov-2021 |
Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 (T315I)-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) |
Qian, Jiang;Shi, Dayu;Li, Zongru;Hou, Yue;Hu, Yu;Li, Weiming;Liu, Xiaoli;Xu, Na;Song, Yongping;Zhang, Gongli;Meng, Li;Hong, Zhenya;Liu, Bingcheng;Li, Yan;Chen, Suning;Xue, Mengxing;Zhu, Huanling;Li, He;Du, Xin;Lou, Jin;Zhang, Xiaohan;Liang, Yang;Dai, Yujun;Chen, Zi;Niu, Qian;Men, Lichuang;Yang, Dajun;Zhai, Yifan;Huang, Xiaojun |
| 15-Nov-2022 |
Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation |
Jiang, Qian;Li, Zongru;Hou, Yue;Hu, Yu;Li, Weiming;Liu, Xiaoli;Xu, Na;Zhang, Yanli;Song, Yongping;Meng, Li;Hong, Zhenya;Liu, Bingcheng;Li, Yan;Chen, Suning;Xue, Mengxing;Zhu, Huanling;Li, He;Du, Xin;Lou, Jin;Zhang, Xiaohan;Liang, Yang;Dai, Yu-Jun;Chen, Zi;Niu, Qian;Men, Lichuang;Yang, Dajun;Zhai, Yifan;Huang, Xiao-Jun |
| 23-Nov-2021 |
Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third -Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) |
Qian, Jiang;Shi, Dayu;Li, Zongru;Qin, Yazhen;Zhao, Ting;Liu, Bingcheng;Chen, Zi;Niu, Qian;Men, Lichuang;Wang, Hengbang;Yang, Dajun;Zhai, Yifan;Huan, Xiaojun |
| 15-Nov-2022 |
Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia |
Zhang, Xiaoshuai;Liu, Bingcheng;Huang, Jian;Zhang, Gongli;Liu, Xiaoli;Xu, Na;Li, Weiming;Du, Xin;Weng, Jianyu;Lin, Hai;Liang, Rong;Chen, Chunyan;Zhu, Huanling;Pan, Ling;Yang, Yunfan;Wang, Xiaodong;Li, Guohui;Liu, Zhuogang;Liu, Zhenfang;Hu, Jianda;Liu, Chunshui;Fei, Li;Yang, Wei;Meng, Li;Gale, Robert Peter;Huang, Xiao Jun;Jiang, Qian |
